Compound Screening TRIZ Cases

A TLR2 antagonist antibody blocks receptor activation to enhance apoptosis and immunostimulatory responses in cancer therapy.

BAFF receptor antibody-siRNA conjugate eliminates multiple booster immunizations by triggering sustained high-affinity antibody production.

An anti-nicastrin antibody binds mature nicastrin to neutralize gamma-secretase activity.

TransposeNet maps molecular pathways underlying alpha-synuclein toxicity, resolving ambiguity in complex gene relationships.

Measuring differentiation markers in cultured oligodendrocytes exposed to patient fluids identifies specific molecular changes.

Fluorescent protein fusion genes label myosin-heavy chain types in muscle stem cells, enabling reliable identification of therapeutic agents for sarcopenia.

Macrocyclic MIF inhibitors block nuclease activity, reducing PARP-1 dependent cell death and DNA fragmentation in neurodegenerative diseases.

Introducing heterologous CDHR3 receptors into conventional cell lines overcomes the inability of standard cultures to support rhinovirus C replication.

Alpha4 integrin antagonists block gp120 interaction to lower viral load without HAART toxicities.

Segmenting mSWI/SNF subcomplexes resolves structural heterogeneity while elucidating how SMARCB1 mutations disrupt nucleosome acidic patch interactions.

Targeting the TrkA/p75NTR receptor balance reduces pro-inflammatory cytokine synthesis while increasing anti-inflammatory mediators to treat chronic diseases.

Transcriptional profiling identifies skin moisturizing actives using specific gene expression biomarkers.

Antithrombin III inhibitors reduce functional protein levels to boost thrombin generation, resolving bleeding risks without systemic thrombo-embolic events.

Segmenting the MUC1 extracellular domain allows targeted ligand binding that inhibits tumorigenesis while simplifying drug design complexity.

Combining SIRT7 detection with miR-125a-5p and miR-125b regulation overcomes low specificity in current liver cancer diagnostics.

Monoclonal anti-RGMb antibodies inhibit the RGMb-PD-L2 receptor interaction, addressing incomplete immune response modulation from known pathways like CTLA4.

Computational screening of calcium-sensing receptor interactions selects compounds that increase kokumi taste and food acceptance in pets.

Formula I compounds inhibit Mcl-1 protein activity, overcoming chemoresistance and inducing tumor regression in breast cancer models.

Discrete droplet formation allows digital counting of enzyme molecules, resolving low-concentration detection limits.

Segmented TfR apical domains overcome blood-brain barrier restrictions, enhancing therapeutic agent uptake into the brain.

Antibodies selectively bind active plasma kallikrein to inhibit enzymatic activity, reducing side effects from off-target protease inhibition.

Three-dimensional spheroid culture models replicate in vivo tissue architecture to screen therapeutic responses from primary patient cells.

A screening method identifies skin tone agents by assessing melanocyte dendricity changes after HMGB1 contact.

Targeting specific intermediary genes blocks translation defect signals, reducing adverse immune responses and improving drug pharmacokinetics.

A screening method identifies compounds disrupting the PFKFB4 and FBXO28 protein interaction to induce tumor cell death.

Segmented AspRS fragments recover non-canonical biological activities masked in full-length proteins, enabling targeted therapeutic applications.

A marker composition uses exosomes overexpressing GCC2 protein to detect esophageal or thymic cancer.

A recombinant reporter system uses protease cleavage to detect ligand binding at G protein-coupled receptors.

A multiplexed fluorescence assay detects antibody binding specificity and tissue cross reactivity using distinct fluorescent labels.

A recombinant PTPRS extracellular domain protein disrupts receptor clustering to inhibit fibroblast-like synoviocyte migration.

Mass spectrometry analyzes spent media metabolite profiles to predict host cell phenotypic performance in industrial cultures.

In vitro assays isolate host-specific variations to provide reproducible assessment of therapeutic agents on microbial communities.

Reporter gene assays identify novel cannabinoids by measuring receptor interactions, overcoming low throughput in traditional screening methods.

Autologous muscle tissue drives fluid flow in a tissue-engineered heart valve, eliminating mechanical wear and thrombogenesis risks.

Neuregulin-4 activates ErbB4 receptors to block cytokine-induced apoptosis and reduce inflammation in intestinal epithelial cells.

Segmenting activation and inactivation kinetics distinguishes CRACM1, CRACM2, and CRACM3 contributions to Icrac activity without physical protein separation.

Developing a brain-specific Alk1 mouse model to identify molecular regulators and test EphB4 inhibitors for treating arteriovenous malformations.

Micropillar arrays act as artificial axons to screen compounds for remyelination, overcoming low throughput in traditional neuronal co-cultures.

A biomarker panel analyzes chronic stress by measuring heat shock proteins and interleukins to overcome hormone test limitations.

Cleavage of a quenched polypeptide by caspase-1 restores fluorescence, enabling real-time imaging without invasive protein extraction.

GALK1-modulating agents restore PTEN/AKT pathway function to treat cancers driven by hyperactivated signaling.

Segmented autoantibody panels resolve specificity versus subgroup differentiation contradictions in systemic sclerosis diagnosis.

A high-throughput assay system identifies positive allosteric modulators for olfactory receptors using isolated cells expressing specific receptor types.

Display systems select protease-resistant peptides from libraries through controlled incubation, maintaining therapeutic efficacy against enzymatic degradation.

Predicting rhTRAIL sensitivity through death receptor expression analysis overcomes acquired resistance and side effects in melanoma treatment.

Targeted KIF6 SNP analysis enables early detection of coronary events while avoiding complex whole-genome sequencing costs.

Recombinant YKL-40 proteins modulate keratinocyte activity to restore barrier function and enhance microorganism defense mechanisms.